Skip to main content
. 2023 Feb 14;58(4):376–381. doi: 10.1177/00185787221142470

Table 2.

Primary Indications for Use of Intravenous Anakinra and 30-Day Survival Rate.

Primary indication N (%) of patients Survival rate—N (%)
MIS-C associated with COVID-19 infection 8 (57.1) 8 (100.0)
HLH 3 (21.4) 1 (33.3)
Systemic onset juvenile idiopathic arthritis flare 2 (14.3) 2 (100.0)
Possible cytokine storm/hyperinflammatory state 1 (7.1) 0

Note. COVID-19 = coronavirus disease 19; HLH = hemophagocytic lymphohistiocytosis; MIS-C = multisystem inflammatory syndrome in children.